Clinical Trial Update: A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion [Phase 3]

View source ↗

Summary

A Phase 3 study of AGA111 for degenerative disc disease in patients undergoing lumbar interbody fusion is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Disc Disease

Drugs mentioned

• AGA111

Snippet

Sponsor: Angitia Biopharmaceuticals | Conditions: Degenerative Disc Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING